Atossa Genetics Net Worth
Atossa Genetics Net Worth Breakdown | ATOS |
Atossa Genetics Net Worth Analysis
Atossa Genetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Atossa Genetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Atossa Genetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Atossa Genetics' net worth analysis. One common approach is to calculate Atossa Genetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Atossa Genetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Atossa Genetics' net worth. This approach calculates the present value of Atossa Genetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Atossa Genetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Atossa Genetics' net worth. This involves comparing Atossa Genetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Atossa Genetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Atossa Genetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Atossa Genetics' net worth research are outlined below:
| Atossa Genetics generated a negative expected return over the last 90 days | |
| Atossa Genetics may become a speculative penny stock | |
| Atossa Genetics has high historical volatility and very poor performance | |
| Net Loss for the year was (30.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Atossa Genetics currently holds about 125.54 M in cash with (20.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99. | |
| Atossa Genetics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Atossa Therapeutics to Present Poster on -Endoxifen at AACR Special Conference in Cancer Research |
Atossa Genetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Atossa Genetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atossa Genetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Atossa Genetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atossa Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atossa Genetics backward and forwards among themselves. Atossa Genetics' institutional investor refers to the entity that pools money to purchase Atossa Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-06-30 | 201.5 K | Two Sigma Investments Llc | 2024-06-30 | 182.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 170.7 K | Qube Research & Technologies | 2024-06-30 | 157.4 K | Rhumbline Advisers | 2024-06-30 | 135.1 K | Mariner Wealth Advisors Llc | 2024-06-30 | 105.9 K | Bank Of America Corp | 2024-06-30 | 105.7 K | Goldman Sachs Group Inc | 2024-06-30 | 102.7 K | Virtu Financial Llc | 2024-06-30 | 75.1 K | Blackrock Inc | 2024-06-30 | 9.2 M | Vanguard Group Inc | 2024-09-30 | 6.6 M |
Follow Atossa Genetics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 149.7 M.Market Cap |
|
Project Atossa Genetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.33) | (0.35) |
When accessing Atossa Genetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Atossa Genetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Atossa Genetics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Atossa Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atossa Genetics. Check Atossa Genetics' Beneish M Score to see the likelihood of Atossa Genetics' management manipulating its earnings.
Evaluate Atossa Genetics' management efficiency
Atossa Genetics has return on total asset (ROA) of (0.2035) % which means that it has lost $0.2035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.313) %, meaning that it created substantial loss on money invested by shareholders. Atossa Genetics' management efficiency ratios could be used to measure how well Atossa Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.36 in 2024. At this time, Atossa Genetics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 4.2 M in 2024, whereas Intangible Assets are likely to drop slightly above 11.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.72 | 0.69 | |
| Tangible Book Value Per Share | 0.72 | 0.69 | |
| Enterprise Value Over EBITDA | (0.72) | (0.75) | |
| Price Book Value Ratio | 1.22 | 1.16 | |
| Enterprise Value Multiple | (0.72) | (0.75) | |
| Price Fair Value | 1.22 | 1.16 | |
| Enterprise Value | -33.1 M | -31.5 M |
The management team at Atossa Genetics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Return On Equity (0.31) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atossa Genetics time-series forecasting models is one of many Atossa Genetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atossa Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Atossa Genetics Earnings per Share Projection vs Actual
Atossa Genetics Corporate Management
| RAC MSPH | VP of Regulatory Affairs and Quality | Profile | |
| Heather CPA | Senior Officer | Profile | |
| Heather Rees | VP Accounting | Profile | |
| FCAP MD | CEO Chairman | Profile | |
| Delly PHR | Vice Resources | Profile | |
| Eric Zanten | Vice Relations | Profile | |
| Richard MD | Interim Officer | Profile |
Already Invested in Atossa Genetics?
The danger of trading Atossa Genetics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atossa Genetics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atossa Genetics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atossa Genetics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.